| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a clinical-stage biotechnology company pioneering novel immunotherapies for cancer and infectious diseases. Headquartered in Boston, Massachusetts, Elicio leverages its proprietary Amphiphile (AMP) platform to develop lymph node-targeted immunotherapies designed to enhance immune responses. The company’s lead candidate, ELI-002, is a therapeutic vaccine targeting KRAS-driven cancers, a mutation prevalent in pancreatic, colorectal, and lung cancers. Elicio’s pipeline also includes ELI-007 for BRAF-mutated cancers, ELI-008 for TP53-expressing cancers, and ELI-005, a COVID-19 vaccine candidate. The AMP technology enables precise delivery of antigens and adjuvants to lymph nodes, potentially improving efficacy compared to traditional immunotherapies. Operating in the high-growth biotechnology sector, Elicio focuses on addressing unmet needs in oncology, positioning itself as an innovator in next-generation cancer vaccines. With no current revenue and a market cap of ~$90.5M, the company remains a high-risk, high-reward investment dependent on clinical success.
Elicio Therapeutics presents a speculative investment opportunity with significant upside tied to its clinical pipeline, particularly ELI-002 for KRAS-driven cancers. The company’s AMP platform offers a differentiated approach to immunotherapy, but its pre-revenue status and net loss of $51.9M (FY 2024) underscore high risk. Diluted EPS of -$4.25 and negative operating cash flow (-$37.1M) highlight reliance on funding to advance trials. The $17.6M cash position (with $26M debt) suggests potential near-term capital needs. Investors should monitor clinical milestones (e.g., Phase 1/2 data for ELI-002) and partnerships. The stock’s beta of 0.93 indicates moderate volatility relative to the market. Suitable for risk-tolerant investors with a long-term biotech focus.
Elicio’s competitive edge lies in its AMP platform, which targets lymph nodes to potentially enhance immune responses versus systemic delivery methods used by peers. This could translate to superior efficacy in cancers with high unmet need (e.g., KRAS-mutated tumors). However, the company faces intense competition from established oncology immunotherapy players like Moderna (mRNA vaccines) and Gritstone Bio (neoantigen vaccines). Elicio’s niche focus on lymph node targeting differentiates it, but its early-stage pipeline lacks the diversification of larger competitors. The absence of revenue also limits scalability compared to commercial-stage peers. Key risks include clinical trial failures, platform validation hurdles, and competition from CRISPR-based therapies (e.g., CRISPR Therapeutics) and TCR-T cell therapies. Strategic partnerships could bolster its position, but current debt ($26M) may constrain flexibility. Success hinges on demonstrating superior clinical outcomes in KRAS/BRAF/TP53 populations.